Before anything else
The math, meaning what the filed numbers justify, shows a company whose top line has shrunk for four straight years and whose reported earnings have been negative in three of the last four. The mood, meaning what the market is currently paying, has sent the stock up sharply over the past twelve months and placed it at a price-to-earnings multiple nearly double its own decade median. The company’s own updated guidance points to adjusted earnings that would make the stock look cheap on a forward basis. Those two readings, a shrinking revenue base and a richly priced stock, cannot both be right without a very specific story about the future. That story is what this audit tests.
Claim one: “Viatris is growing again”
Viatris was born in November 2020 from the merger of Mylan and Pfizer’s off-patent drug unit, Upjohn. The logic was scale: combine Mylan’s generics pipeline with Upjohn’s established brands and squeeze out a billion dollars in cost savings. What followed was not quite the script. Revenue peaked at $17.8 billion in 2021 and has fallen every year since, reaching $14.7 billion in the fiscal year ended December 2024, according to the 10-K filed for FY2024. The company sold off its biosimilars unit, its women’s healthcare business, its over-the-counter brands, and its Indian API operation between 2022 and 2024, collecting roughly $6.9 billion in gross proceeds. Each sale made the company leaner and, by design, smaller.
So when the Q2 2026 earnings call on August 6 produced headlines about growth, the word needed context. Total revenues for the quarter were $3.8 billion, a modest operational increase year-over-year, the kind of increase that, annualized, roughly matches the pace of the broader economy. The standout was Greater China, where revenues rose sharply, driven by cardiovascular drugs and a surge in e-commerce sales. That is real momentum. But Developed Markets, the largest segment, grew only slightly, and Emerging Markets actually shrank due to supply problems in the antiretroviral generics portfolio.
The filed revenue trend, four consecutive years of decline from 2022 through 2025, is the math. One quarter of modest operational growth is the mood’s preferred exhibit. A saver deciding how much weight to give each should note that the company’s own interim CFO, Paul Campbell, flagged on the August 6 call that second-half 2026 faces headwinds including a procurement policy change in Greater China and fresh competitive pressure in North American inhalers, plus a meaningful revenue hit from supply disruptions at its Nashik facility. Growth that arrives in the first half and faces headwinds in the second is not the same as a durable inflection.
Claim two: “The valuation is cheap on a forward basis”
This is the claim with the most arithmetic behind it, and it deserves a careful look. The company’s own updated guidance, issued on August 6, puts adjusted earnings per share for full-year 2026 in a range whose midpoint, divided into the current stock price, produces a forward price-to-earnings multiple around 6.4. For a pharmaceutical company, that is low. Analyst consensus for the following year would push that multiple even lower.
The catch is the word “adjusted.” Adjusted earnings strip out restructuring charges, amortization of acquired drug patents, and other items the company deems non-recurring. The trailing reported EPS, the number that actually landed in shareholders’ accounts, was deeply negative in both FY2024 and FY2025, per the 10-K for fiscal year 2025. Viatris itself does not provide forward guidance for GAAP net earnings, the standard accounting measure, precisely because the gap between adjusted and reported is wide and hard to predict. Our data show the trailing P/E is currently negative (reflecting negative reported earnings), against a ten-year average of 87.2 that has ranged widely given the company’s volatile earnings history. The forward multiple of 6.4 is real only if adjusted earnings are the right denominator, and that is a judgment call, not a fact.
The EV/EBITDA multiple, which compares the total price of the business to its operating earnings before interest and taxes, sits above the company’s own five-year average. So on this measure, the stock is not cheap relative to its own history; it is slightly above the midpoint of its recent range.
Claim three: “The debt load is under control”
Viatris carried roughly $13.35 billion in long-term debt as of June 30, 2026, per the Q2 2026 10-Q. To put that in kitchen-table terms: the debt pile is nearly equal to a full year of company revenue, meaning Viatris would have to hand over essentially everything it earns for twelve months just to clear the balance. Interest alone consumed roughly ten cents of every operating dollar last quarter before anything else. The company repaid a large tranche of debt that came due in June 2026, which is a genuine positive, and its gross leverage ratio sits inside its own stated target range.
The February 2026 restructuring, which targets thousands of job cuts over three years and hundreds of millions in annual savings, is designed to generate the cash that services this debt while also funding the pivot toward specialty drugs. Free cash flow for Q2 2026 was healthy. Whether it holds in the second half, when the Nashik supply disruption and China procurement changes bite, is the open question the filings cannot yet answer.
Reading the numbers
$3.8 billion in Q2 2026 revenue. This is what the company collected from customers in the three months ended June 30, 2026, per the Q2 2026 10-Q. It matters because it is the first quarter in several years to show operational growth across the consolidated business. Think of it as a household whose monthly income had been falling for four years finally posting a small raise, but with the boss already warning that the next two paychecks may be smaller.
Adjusted EPS guidance of $2.45 to $2.59 for full-year 2026. Adjusted EPS is earnings per share with certain costs removed, a measure the company controls the definition of. At the midpoint of $2.52, divided into the $16.54 stock price, the forward multiple is about 6.4. A multiple is simply the price tag per dollar of profit: paying 6.4 times earnings means paying $6.40 for every $1 the company expects to earn. That is low by pharmaceutical industry norms, but the denominator is adjusted, not reported, earnings.
$13.35 billion in long-term debt. This is money owed to lenders, due over various future dates. It is nearly equal to a full year of company revenue, meaning Viatris would have to hand over essentially everything it earns for twelve months just to clear the balance, with nothing left for operations. The 2.9 times leverage ratio means the debt pile is 2.9 times the company’s annual operating profit. A family with $2.9 in debt for every $1 of annual take-home pay is not in crisis, but it has limited room for surprises.
54.7% stock gain over the past twelve months. This is the mood number, the market’s verdict on the turnaround story. Our data show the price-to-sales multiple, the price per dollar of revenue, at 1.3 times, in the 82nd percentile of the company’s own decade range. The market is paying more for each dollar of Viatris revenue than it has in roughly eight of the last ten years. That premium is a bet on the specialty pivot succeeding. The filings show the pivot is underway; they do not yet show it is complete.
For the standing yardsticks on Viatris: the price tag, the filed record, and the four gauges, refreshed with each edition, see the BullScope Evidence Sheet: Viatris.
Sources
- Viatris Q2 2026 earnings press release, PR Newswire, August 6, 2026
- Viatris Q2 2026 earnings call transcript, Motley Fool, August 13, 2026
- Earnings call transcript, Investing.com
- Q2 2026 earnings call highlights, GuruFocus
- Viatris Q2 2026 10-Q summary, Moomoo
- Viatris research deep dive, Financial Content, March 2026
- Viatris raises 2026 outlook, Seeking Alpha
- 10-Q for quarter ended June 30, 2026, SEC EDGAR
- 10-K for fiscal year ended December 31, 2025, SEC EDGAR
- 10-K for fiscal year ended December 31, 2024, SEC EDGAR
